Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEPHYR: Voxelotor in IPF with Hypoxemia
NCT02989168Phase 2Terminated
- Sponsor
- Global Blood Therapeutics
- Start
- Nov 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of voxelotor in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Global Blood Therapeutics. Primary endpoint: Change in Oxygen Saturation at 90 days. Started Nov 2016; status: terminated.
02
Drugs
voxelotor
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02989168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989168.